NFKB1 and lymphoma: To confirm the significance of TAK1-mediated MYD88L265P signaling on lymphoma cell growth, the effect of the selective TAK1 inhibitor, (5Z)-7-Oxozeaenol, on cell proliferation was tested; an NF-κB inhibitor was included as a control (Figure 4a).25 All MYD88L265P-expressing cell lines were sensitive to TAK1 and NF-κB inhibition in a dose-dependent manner (0–10 μM) (Figure 4a).